D A T E K S
Yaşamkent mah. 3061.Cadde No:38 Çankaya Ankara TÜRKİYE dateks@dateks.com
English

Address

Efferon LPS Adsorption Column

Founded in 2016, Efferon is a creator and manufacturer of next-generation therapeutic devices to treat sepsis and multiple organ failure syndrome through extracorporeal blood purification. The company's flagship product, Efferon LPS, a single-use medical device for hemoperfusion, received CE mark approval under the EU MDR in April 2024. The safety and efficacy of Efferon LPS has been validated in multicenter randomized clinical trials and more than 10,000 critically ill patients have been treated.

Efferon.pdf

Efferon ® LPS

Disposable therapeutic device for extracorporeal blood adsorption.

  • Polymeric adsorbents for selective removal of bacterial endotoxins and cytokines.

  • Extracorporeal therapy for sepsis and multiple organ failure

  • A safe and effective method for stabilization of critically ill patients


Indications

  • Sepsis of confirmed or suspected gram-negative etiology, including septic shock

  • Destructive diseases of the gastrointestinal tract leading to LPS translocation and endotoxemia


Intended Use

The device is intended for extracorporeal blood purification by direct hemoperfusion or in combination with hemofiltration. Detoxification is carried out by selective adsorption of lipopolysaccharides (bacterial endotoxins) and excess endogenous inflammatory mediators. Timely administration allows stabilizing hemodynamic parameters and preventing the development of multiple organ failure.